These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 6316420)

  • 21. Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation.
    Aiken JW; Gorman RR; Shebuski RJ
    Prostaglandins; 1979 Apr; 17(4):483-94. PubMed ID: 111306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Demonstration of PGI2 production by isolated perfused rat lungs with platelet aggregation test.
    Hartiala J; Toivonen H; Uotila P
    Prostaglandins; 1980 Jul; 20(1):127-34. PubMed ID: 6996035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic inhibition of platelet activation by plasmin and prostaglandin I2.
    Schafer AI; Zavoico GB; Loscalzo J; Maas AK
    Blood; 1987 May; 69(5):1504-7. PubMed ID: 3032310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of the antiaggregatory activity of prostacyclin by propranolol in human platelets.
    Callahan KS; Johnson AR; Campbell WB
    Circulation; 1985 Jun; 71(6):1237-46. PubMed ID: 2986877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostaglandin I2 (PG I2) fails to inhibit ADP induced platelet aggregation in vivo in rats.
    Zehl U; Förster W
    Prostaglandins Leukot Med; 1984 Oct; 16(1):45-56. PubMed ID: 6393144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute reversible reduction of PGI2 platelet receptors after iloprost infusion in man.
    Modesti PA; Fortini A; Poggesi L; Boddi M; Abbate R; Gensini GF
    Thromb Res; 1987 Dec; 48(6):663-9. PubMed ID: 2448896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo studies with the stabilized epoprostenol analogue taprostene. Effects on platelet functions and blood clotting.
    Michel G; Seipp U
    Arzneimittelforschung; 1990 Aug; 40(8):932-8. PubMed ID: 2242087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet sensitivity to adenosine diphosphate and to prostacyclin in diabetic patients.
    Onodera H; Hirata T; Sugawara H; Sugai K; Yoda B; Toyota T; Goto Y
    Tohoku J Exp Med; 1982 Aug; 137(4):423-8. PubMed ID: 6750843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of clinical prostacyclin infusions in advanced arterial disease on platelet function and plasma 6-keto PGF1 alpha levels.
    Machin SJ; Chamone DA; Defreyn G; Vermylen J
    Br J Haematol; 1981 Mar; 47(3):413-22. PubMed ID: 7006673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of inhibitory actions of prostacyclin and a new prostacyclin analogue on the aggregation of human platelet in whole blood.
    Saniabadi AR; Belch JJ; Lowe GD; Barbenel JC; Forbes CD
    Haemostasis; 1987; 17(3):147-53. PubMed ID: 2440771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of platelet aggregation with intravenous and oral administration of carboprostacyclin in man.
    Karim SM; Adaikan PG; Lau LC; Tai MY
    Prostaglandins Med; 1981 May; 6(5):521-7. PubMed ID: 7022510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of taprostene, a stable prostacyclin analogue, on haemodynamics, platelet function and arachidonate metabolism in healthy volunteers.
    Virgolini I; Fitscha P; Sinzinger H; Barth H
    Eur J Clin Pharmacol; 1990; 38(4):347-50. PubMed ID: 2111774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species.
    Nishio S; Matsuura H; Kanai N; Fukatsu Y; Hirano T; Nishikawa N; Kameoka K; Umetsu T
    Jpn J Pharmacol; 1988 May; 47(1):1-10. PubMed ID: 2842529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro effects of ethanol on rabbit platelet aggregation, secretion of granule contents, and cyclic AMP levels in the presence of prostacyclin.
    Rand ML; Gross PL; Jakowec DM; Packham MA; Mustard JF
    Thromb Haemost; 1989 Apr; 61(2):254-8. PubMed ID: 2546284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent.
    Miller OV; Aiken JW; Shebuski RJ; Gorman RR
    Prostaglandins; 1980 Aug; 20(2):391-400. PubMed ID: 6251513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of age, sex, and the use of oral contraceptives on the inhibitory effects of endothelial cells and PGI2 (prostacyclin) on platelet function.
    Nordøy A; Svensson B; Haycraft D; Hoak JC; Wiebe D
    Scand J Haematol; 1978 Sep; 21(3):177-87. PubMed ID: 362511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo interaction of prostacyclin with an inhibitor of cyclic nucleotide phosphodiesterase, HL 725.
    Darius H; Lefer AM; Leprán I; Smith JB
    Br J Pharmacol; 1985 Mar; 84(3):735-41. PubMed ID: 2985163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition and subsequent enhancement of platelet responsiveness by prostacyclin in the rabbit. Relationship to platelet adenosine 3',5'-cyclic monophosphate.
    Vanderwel M; Haslam RJ
    J Clin Invest; 1985 Jul; 76(1):233-40. PubMed ID: 2991338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function.
    Fisher CA; Kappa JR; Sinha AK; Cottrell ED; Reiser HJ; Addonizio VP
    J Lab Clin Med; 1987 Feb; 109(2):184-90. PubMed ID: 2433373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostacyclin (PGI2) inhibits the development in human platelets of ADP and arachidonic acid-induced shape change and procoagulant activity.
    Ehrman ML; Jaffe EA
    Prostaglandins; 1980 Dec; 20(6):1103-16. PubMed ID: 7010448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.